10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

C3orf49 Rabbit pAb

C3orf49 Rabbit pAb
Catalog # AP59402

Product Information

Application	IHC-P, IHC-F, IF
Primary Accession	Q96BT1
Predicted	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	33461
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human C3orf49
Epitope Specificity	201-292/292
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	C3orf49 is a 292 amino acid protein encoded by a gene that maps to human chromosome 3p14.1. Chromosome 3 is made up of approximately 214 million bases encoding over 1,100 genes. Notably, there is a chemokine receptor gene cluster and a variety of human cancer related loci on chromosome 3. Particular regions of the chromosome 3 short arm are deleted in many types of cancer cells. Key tumor suppressing genes on chromosome 3 encode apoptosis mediator RASSF1, cell migration regulator HYAL1 and angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth disease are a few of the numerous genetic diseases associated with chromosome 3.

Additional Information

Gene ID	132200
Other Names	Putative uncharacterized protein C3orf49, C3orf49
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name C3orf49

Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.